Fenofibrate CAS 49562-28-9 proctofene sedufen lipidax lipifen

Place of Origin: Shandong,China (Mainland)
CAS: 49562-28-9


skype basketAdd to Basket  Edit

Share |

Product Description

Payment & Shipping Terms Supply Capacity
Payment Terms:L/C, T/T, WUProduction Capacity:100 Ton/Year
Min. Order:1 KilogramPacking:According to the...
Means of Transport:Ocean, Air, LandDelivery Date:Within 7 days

Fenofibrate(CAS: 49562-28-9)



Molecular formula


Molecular weight





Off-white powder

Melting point


 Storage   Condition

Store at RT


Fenofibrate (Tricor) is a drug of the fibrate class. It is mainly used to reduce cholesterol levels in patients at risk of cardiovascular disease. Like other fibrates, it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglycerides level. It is used alone or along with statins in the treatment of hypercholesterolemia andhypertriglyceridemia.

Fenofibrate has been used since 1975, is one of the most commonly prescribed fibrates, and has a well known efficacy and tolerability profile.

Medical uses

Fenofibrate is mainly used for primary hypercholesterolemia or mixed dyslipidemia. It is used in addition to diet to reduce elevated low-density lipoprotein cholesterol (LDL), total cholesterol, triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL) in adults with primary hypercholesterolemia or mixed dyslipidemia.

Severe hypertriglyceridemia type IV or V

Indicated as an adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention.

Three randomized, double-blind trials have shown that treatment with fenofibric acid plus a statin improved HDL and triglyceride levels better than a statin alone and improved LDL levels better than fenofibric acid monotherapy.

Fenofibrate appears to decrease the risk of cardiovascular disease and possibly diabetic retinopathy in those with diabetes mellitus.

Additionally, in Europe, fenofibrate is indicated in mixed hyperlipidemia in those with high cardiovascular risk in addition to a statin when triglycerides and HDL are not adequately controlled.

Category: Circulatory System Drugs API

Related Category: Vitamin Preparation API  Psychotropic Drugs API  Endocrine Drugs API  Digestive System Drugs API  Insect Repellent API 

Offline Showroom in USA
QR Code